MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-01-2026
China Pharma Holdings DPO Ratio 2011-2026 | CPHI
Annual DPO Ratio China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.6 | 33.4 | 40.9 | 33.8 | 42.4 | 50.6 | 52.8 | 37.4 | 38.8 | 90.4 | 54.6 | 47.8 | 20.6 | 25.7 | 21.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 90.4 | 20.6 | 42.6 |
Quarterly DPO Ratio China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.6 | 44.2 | 27.7 | - | 15 | - | - | - | 27.9 | 46.3 | 38.8 | - | 18.1 | 32.8 | 47.7 | - | 25.8 | 35 | 51.3 | - | 47.9 | 43 | 75.6 | - | 62.2 | 51.8 | 48.7 | - | 54.2 | 37.3 | 39.2 | - | 38 | 45.9 | 74.7 | - | 101 | 91.3 | 83.7 | - | 69.3 | 57.1 | 55.3 | - | 57.4 | 62.7 | 45.5 | - | 29.2 | 29.3 | 35.1 | - | 29 | 37.9 | 37.9 | - | 19.9 | 10.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 | 10.2 | 46.3 |
DPO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
38 | - | 7.5 % | $ 6.35 M |  USA |
 |
Cronos Group
CRON
|
212 | $ 2.58 | 1.98 % | $ 1.37 B |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
345 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
116 | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
122 | $ 19.26 | 0.26 % | $ 123 M | USA |
 |
Agile Therapeutics
AGRX
|
352 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
309 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
111 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
224 | - | - | $ 2.06 B |  France |
 |
Bausch Health Companies
BHC
|
78.1 | $ 5.41 | 1.12 % | $ 1.97 B | Canada |
 |
Aurora Cannabis
ACB
|
-807 | $ 3.44 | - | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
52.8 | $ 1.02 | 2.0 % | $ 110 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
775 | $ 3.1 | -2.21 % | $ 43.6 M | USA |
 |
Catalent
CTLT
|
41.8 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
519 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
75.6 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
39.3 | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
59.4 | $ 4.16 | 3.23 % | $ 268 M | USA |
 |
Emergent BioSolutions
EBS
|
55.8 | $ 8.1 | -1.58 % | $ 415 M | USA |
 |
Evoke Pharma
EVOK
|
5.36 K | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
199 | $ 35.13 | -0.51 % | $ 1.29 B | USA |
 |
Jupiter Wellness
JUPW
|
318 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
36.8 | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
194 | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
94 | $ 2.24 | - | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
37.3 | $ 22.27 | -1.89 % | $ 1.03 B | USA |
 |
PetIQ
PETQ
|
54.2 | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
45.4 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
274 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
6.63 | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
15.4 | $ 0.96 | 0.84 % | $ 34.5 M | USA |
 |
SCYNEXIS
SCYX
|
20.2 | $ 0.92 | 3.28 % | $ 45.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
32.3 | $ 2.33 | -1.9 % | $ 2.89 M | USA |
 |
Tilray
TLRY
|
53 | $ 6.66 | 1.68 % | $ 4.12 B | Canada |
 |
Veru
VERU
|
264 | $ 2.4 | 4.8 % | $ 324 M | USA |
 |
Viatris
VTRS
|
64 | $ 13.41 | -0.22 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
84 | $ 0.73 | -0.4 % | $ 3.15 M | USA |
 |
Zomedica Corp.
ZOM
|
64.3 | - | -0.21 % | $ 98 M | USA |
 |
TherapeuticsMD
TXMD
|
723 | $ 2.2 | 10.0 % | $ 25.5 M | USA |